Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
Most if not the majority of Amarin's press releases result in a share price loss. I periodically add shares (risk assumed), but also my bet of optimism is: Either revenue profits will change WS's punishing outlook on Amarin, a potential buy-out though at some point such a possibility will begin to fade, or some true catalyst like a just-judgment against generics, or France, Italy, and Germany join the Vazkepa party. Science never seems to interest WS, nor patents (but that recent bit of news definitely adds to revenue potential). It's all IMO but until that revenue stream begins to really move, we're stuck and I can't believe Denner, Holt, the Board, Amarin leadership, employees want that. Holt really needs to address, 'How do you plan to get this revenue stream much, much higher?' because even the vast landscape of the competitive USA opportunity is being wasted each and every day. Bullish as ever.
Granted 2039 EU exclusivity. Huge valuation news.
I am posting only because I haven't read what I will now state: The TRUTH is being told, plain and simple. TRUTH prevails when honest judges committed to the TRUTH see their role as getting at the TRUTH. Judge Moore is focused as were her fellow judges on the most basic of all principles: TRUTH. Has Hikma infringed? Yes, that is the TRUTH. Prediction: Amarin will prevail because now they have a lawyer (team) focused on TRUTHFUL FACTS. Sadly, in the previous trials, Amarin unfortunately got corrupt politically motivated judges. TRUTH will also one day take this stock back into double digits. Thank you for your time.
"Sell in May" I wait a bit, but add another 10,000 shares in advance of buy-back. I mean, why not? Who else is loading up in advance of buy-back?
Upside to Dark Naked Shorts?
Astronomical pps jump: $80 per share
Entire manipulation.
It’s entirely PERCEPTION
“Better than slice cheese which clogs veins, Vascepar unclogs damaged pathways.”
Holt et al should announce a $50M to now $100M share buyback based upon market conditions and no BOD share awards including CEO unless they surpass 2023 earnings. Id even suggest greater stock compensation for Holt et al if they return 25% greater revenue or a stock price over $10 share by 31 December 2024..
Holt wt al should announce a $50M to now $100M share buyback based upon market conditions and no BOD share awards including CEO unless they surpass 2023 earnings.
Team Holt mishandled today n now owe all of us corrective action. Holt embarrassed all of us. So the market pounced.
i would remind everyone holt’s biggest payday is above $15 per share. seeing how Holt’s investing he’ ll drive the price much higher.
“Amarin Announces It’s Going After US Pot of Gold”.
What I got out of the press release which was not stated at the recent conference is the disclosure a new initiative is in motion not just to retain US market share, but to grow the market further. This is more than a business nuance but a stated intent to add growth in the US. Holt et al realize what i told Denner; Vascepa hasn’t even begun to tap the revenue opportunity which remains in the US so why not go after it? No doubt Berg feels the same way, however the strategy is via preferred brand, and at the right time releasing their own generic. This US news initiative implies Holt et al are not giving up but actually going after the US pot of gold .
while i have one account deeply under water i have another account near denner. after listening to holt in time i hope to add many more shares. this stock is an very easy double and much much highet
Management (including Denner) are listening as I promoted the stock buy-back. It's a savvy move and it's justifiable and it shows how well Denner n team understand market dynamics. Anyone buying shares now is going to see a thousand plus return. Glad I bought more shares in months gone by. Solid drug. And with Holt n team, heading in the right direction.
As an older investor in biotech land, I would strongly caution newer biotech investors not to be drawn into the speculation of anyone supposedly citing a source who may be drunk in a pub that the BRAVE study results are known. I do my own due diligence as I have an email from the VA stating while the study is completed it can take up to 12 months before results are published.
Use a little logic. This is a really huge population study just to start. A third party is hired and paid to do the analysis without any skin in the game. We were informed the study completed in September and there's no way in Hell or Earth the analysis was completed. Are you aware of the study size? It's huge and there are so many statistics etc to be drawn out anyone expecting results is SIMPLY EITHER LYING OR PLAYING WITH YOUR MIND.
Vascepa may or may not prove to help with Alzheimer's but when you've spent millions, and many years, you know the analysis and then public report must reflect non-bias analysis--thus a third party is hired to go over the study.
Frankly, I don't care who said what as I am currently in personal contact with the lead investigator. Not someone, anyone, on a message board.
Who here is aware after spending millions of dollars on a clinical study, the host party more frequently than not turns all the data over to a paid hired party whose job is to do the statistical analysis which never happens in days, more like months because no one wants to get the results wrong. Furthermore, there are subsets of data which can turn out to be just as important as witnessed by Amarin's ongoing studies of the Reduce-It data.
I find this entire notion someone let something slip is incredulous and highly doubtful; I am however attacking no one as it's my own observation how message boards work. The results are not known until published and not too surprisingly it looks like it will happen in 2024. BTW, writing up the results for publication is a time consuming effort as well, so all I see here with some is a lack of understanding how after you spend oodles of dollars and many years conducting a clinical study, they are doing all the due diligence pro or con.
Regarding my post I received an email from VA which in no wise reflected on yay or nay only the study is completed n they have 12 months to report.
i personally will state that turnaround time to that conference was way too short as it’s more like 4 or months to crunch all the data.
i would caution all, the results are not public n everything else is speculation.
VA answered inquiry stating it was completed but they have a “12 month” window for reporting results so it hasn’t happened.
Here's why you believe in $50/share...
You'll sleep much better. I can barely get out of bed seeing it rise to a dollar! You see I'm a believer! Use your mind to create your reality. Pour great news into the stock. See Amarin conquering Alzheimer's and believe it! Dream Holt shakes you in your sleep to shout out: "I just sold Amarin for $134 and you're absolutely rich!" Now stay there... create by your words that reality...
$49.12 cents to go! You gotta love it! Can't wait for Dec 2026! We'll all be laughing, sharing stories of investor savvy, everyone will be friends, and those we put on ignore we'll release from the abyss.
Somebody didn't think twice to buy 3,757,302 shares at the close. Who sold doesn't matter. Someone has put big skin in the game. That's what matters.
no offense but did anyone notice who bought it?
Does anyone know? My doctors over the years sometimes have samples of drugs as I've gotten a few freebies along the way. Thus my question: If Amarin is overstocked with Vascepa, why not send freebie packs to physicians with paperwork introducing the drug? Thanks for any educated answers as I've long pondered this.
I hope real savvy investors are viewing CaptBeer.
Vascepa-Vazkepa is outpacing cost at a profit and unless I'm corrected, I think the UK has joined the USA in profitability.
Friends, AMRN profitability is taking off in 2024.
well if 400k capsules is around 13,333 scripts let's say $80 profitability that's $1,066.6667 so is overhead more than $300K per month?
Ques to Captain or others. Seeing the script growth will be 300-400K (Q4) in the UK is it now at a point where Vazkepa is now self-producing enough to cover all UK expenses, and hopefully profits? How many scripts there do we need to be break even and then making revenue? Thanks I think many would like an answer.
The Possible Treatment Connection between Vascepa (Icosapent ethyl) and Alzheimer's Disease
Dr. Black in Sweden noted Icosapent ethyl in cardiovascular prevention: Resolution of inflammation through the eicosapentaenoic acid - resolvin E1 - ChemR23 axis that icosapent ethyl..." EPA is a substrate for the enzymatic metabolism into the lipid mediator resolvin E1 (RvE1), which activates the receptor ChemR23 to transduce an active resolution of inflammation".
We go on to note in Alzheimer's ... this ChemR23 connection was recognized years ago Resolution of inflammation is altered in Alzheimer's disease but more recently ChemR23 in ALZ
The anti-inflammation effect may prove useful in delaying the onset of Alzheimer's disease.
Medical Community Alert: Benefit of icosapent ethyl on coronary physiology assessed by computed tomography angiography fractional flow reserve: EVAPORATE-FFRCT
Amarin's Vascepa/Vazekpa is a necessary medicament for coronary heart disease and must be immediately scripted to all patients at risk of dying or suffering a heart attack or stroke.
"Conclusion: Icosapent ethyl demonstrated significant benefits in coronary physiology compared with placebo."
"There was significant improvement in the primary endpoint, as IPE improved mean distal segment FFRCT at 9- and 18-month follow-up compared with placebo (0.01 ± 0.05 vs. -0.05 ± 0.09, P = 0.02, and -0.01 ± 0.09 vs. -0.09 ± 0.12, P = 0.03, respectively). ?FFRCT in 140 coronary lesions was improved, although not statistically significant, with IPE compared with placebo (-0.06 ± 0.08 vs. -0.09 ± 0.1, P = 0.054). "
$50 pps is our focus. If it's not yours, it can be mine with Alzheimer's.
Mr. Zwick had a gravy job from his home in the Carolinas! He did not survive Holt who is transforming the company. It's why Denner and I see the pps exploding. Bye, bye Jordan you needed to go last month! No really, you needed to go in 2022! What a total waste!
Everyone is saying it, "Holt says so where do you add value?" and then the decision comes. Zwick who works from home was out... out... out...
I love the new Amaran $55pps! Did you see how we're growing scripts in the USA despite competition? It's impressive.
GONE! Mr. Jordan Zwick. Not surprised about this one as he wasn't delivering value to Holt's team.
I love $50pps!
I believe we will soon go over $1pps showing the sheer power of Sarissa. Criticize me if you must, but I think a major move higher is in the works!
I see I've been chided for having silly pps dreams. That's okay, I think everyone has the right to dream because sometimes dreams come true. I remember owning 100,000 shares @ 20 cents for a N Dakota oil and gas company that I later sold around $1--I felt plenty silly happy that day! I guess it comes down to what you think is possible and I've learned the biotech sector anything good or bad can happen, but if we get good Alzheimer's news, I'll be silly happy @ $50 pps. Anyone else want to feel silly?
I find myself encouraged by the price going up again today. I remain in Holt and Denner's corner as I believe great things are ahead for this company. Give me $50 pps and I'd truly be happy. Well, let's see what happens on the Alzheimer's front.
All I know is Sarissa talked publicly and it got an intended reaction. I can only hope this will go over $1. Stay positive everyone!
I saw my Amarin investment went up 2.27% today and I felt pretty good about that. Seems like a lot of positives out there!
I enjoy IHUB as I use the 'ignore' option, but I'm actually here for Amarin. I get the clear read Holt is doing what is necessary to build a great firm based on an even greater drug. I hold separate accounts so profitability is very close on one while the other is further out. That said it's exciting to think how Alzheimer's might come into play. I wish everyone the very best!
I stand with Holt et al.
A better day is ahead. Feeling very positive.
EPA (Vascepa) showed an efficacy use in dementia and Alzheimer's irrespective of genetics which remains open to analysis as the EPA amount didn't necessarily follow the regiment. Not only did the German study demonstrate this, Budoff's earlier work demonstrated EPA's effect elsewhere.
The BP buying out Amarin is preparing for patent battles and Teva type companies coming after you. IMO, Amarin should advertise odd commercials in the USA to say to generics, 'We haven't gone away.'
I still don't understand why a modest 50 staff sales force cannot be sustained in the USA. I say grow Vascepa in the USA. Let it's value shine irrespective of generics.
People without the gene also get dementia n Alzheimer’s and this is a large population plus a proper dose study may be called for those with gene
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC7912244/
German study link proving Vascepa delays dementia n Alzheimer’s
As we cited in a German study, Vascepa delayed dementia and Alzhheimer's in those not having a particular gene
As 'cheap' as Vascepa is you can expect the FDA will be all over it as will everyone. Amarin sits on more patents.
I continue to believe this is going to ignite a massive run in the pps (IMO). It will make Reduce It look small.